Cancer gene therapy using a novel secretable trimeric TRAIL

[1]  B. Fang,et al.  Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter , 2005, Cancer Gene Therapy.

[2]  D. Seol,et al.  The secretable form of trimeric TRAIL, a potent inducer of apoptosis. , 2004, Biochemical and biophysical research communications.

[3]  P. Chiao,et al.  Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  B. Pyrzyńska,et al.  TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways , 2003, Brain pathology.

[5]  D. Frank.  Gene therapy for head and neck cancer. , 2002, Surgical oncology clinics of North America.

[6]  T. Griffith,et al.  Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  B. Davidson,et al.  Adenoviral-Mediated Transfer of the TNF-Related Apoptosis-Inducing Ligand/Apo-2 Ligand Gene Induces Tumor Cell Apoptosis1 , 2000, The Journal of Immunology.

[8]  K. Famulski,et al.  Functional analysis of tumour necrosis factor-α-related apoptosis-inducing ligand (TRAIL): cysteine-230 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine , 2000 .

[9]  D. Seol,et al.  Cysteine 230 modulates tumor necrosis factor-related apoptosis-inducing ligand activity. , 2000, Cancer research.

[10]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[11]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[12]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[13]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[14]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[15]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[16]  J. Blenis,et al.  Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade , 1998, Current Biology.

[17]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[18]  M. Weller,et al.  APO2 ligand: a novel lethal weapon against malignant glioma? , 1998, FEBS letters.

[19]  Stefan Grimm,et al.  The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal , 1998 .

[20]  G. Salvesen,et al.  Caspases: Intracellular Signaling by Proteolysis , 1997, Cell.

[21]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[22]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[23]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[24]  M. Kitamura,et al.  Construction of adenovirus vectors through Cre-lox recombination , 1997, Journal of virology.

[25]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[26]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[27]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[28]  A. Chinnaiyan,et al.  FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis (*) , 1996, The Journal of Biological Chemistry.

[29]  R. Leduc,et al.  Furin/PACE/SPC1: A convertase involved in exocytic and endocytic processing of precursor proteins , 1996, FEBS letters.

[30]  Hong-Bing Shu,et al.  TRADD–TRAF2 and TRADD–FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways , 1996, Cell.

[31]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[32]  P. Galle,et al.  Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage , 1995, The Journal of experimental medicine.

[33]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[34]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[35]  J. Camonis,et al.  A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain (*) , 1995, The Journal of Biological Chemistry.

[36]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[37]  A. Alavi,et al.  Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. , 2001, Human gene therapy.

[38]  W. Walther,et al.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases. , 2000, Drugs.

[39]  P. Leder,et al.  The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. , 1998, Immunity.

[40]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. , 1995, Cell.